Anders sterborg

List of Publications by Year in Descending Order

122 papers	2,533 citations	25 h-index	47 g-index
124 ext. papers	3,249 ext. citations	4.9 avg, IF	4.49 L-index

#	Paper	IF	Citations
122	Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.. *Nature Medicine*, **2022**,	50.5	59
121	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals.. *Med*, **2022**,	31.7	5
120	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.. *Molecular Medicine*, **2022**, 28, 20	6.2	2
119	Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukemia?. *Scandinavian Journal of Immunology*, **2022**, e13153	3.4	1
118	Mutations of the Novel Tumor Suppressor Gene SAMHD1 Are Frequent and Correlate with Decreased Protein Expression in Peripheral T-Cell Lymphomas (PTCL). *Blood*, **2021**, 138, 3515-3515	2.2	
117	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. *Blood*, **2021**, 138, 70-70	2.2	8
116	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EBioMedicine*, **2021**, 74, 103705	8.8	34
115	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. *Haematologica*, **2021**, 106, 87-97	6.6	17
114	Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules. *Handbook of Experimental Pharmacology*, **2021**, 269, 75-99	3.2	1
113	A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1+ CLL cells. *EJHaem*, **2021**, 2, 498-502	0.9	1
112	BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. *Frontiers in Immunology*, **2021**, 12, 686768	8.4	4
111	Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions: Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. *EJHaem*, **2021**, 2, 525-529	0.9	0
110	Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. *Leukemia*, **2021**,	10.7	5
109	Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells. *Prostaglandins and Other Lipid Mediators*, **2021**, 156, 106575	3.7	1
108	ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. *Biomedicines*, **2020**, 8,	4.8	10
107	Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report. *British Journal of Haematology*, **2020**, 189, 689-693	4.5	
106	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. *Blood*, **2020**, 136, 45-49	2.2	2

105	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. *Blood*, **2020**, 136, 11-12	2.2	13
104	Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. *Haematologica*, **2020**, 106, 2354-2363	6.6	28
103	A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy. *Leukemia and Lymphoma*, **2020**, 61, 2136-2144	1.9	3
102	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. *Blood*, **2020**, 136, 1134-1143	2.2	132
101	Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients. *British Journal of Haematology*, **2020**, 191, 426-432	4.5	1
100	Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies. *Journal of Immunological Methods*, **2020**, 476, 112675	2.5	3
99	Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application. *Cancers*, **2019**, 11,	6.6	15
98	PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping. *Blood*, **2019**, 134, 4304-4304	2.2	5
97	HAX-1 overexpression in multiple myeloma is associated with poor survival. *British Journal of Haematology*, **2019**, 185, 179-183	4.5	4
96	NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation. *Blood*, **2019**, 134, 2796-2796	2.2	
95	First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. *Haematologica*, **2019**, 104, 797-804	6.6	18
94	Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. *Haematologica*, **2019**, 104, e208-e210	6.6	32
93	Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. *European Journal of Haematology*, **2018**, 101, 68-77	3.8	11
92	Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes. *British Journal of Haematology*, **2018**, 183, 212-224	4.5	11
91	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. *British Journal of Haematology*, **2018**, 182, 504-512	4.5	32
90	A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. *PLoS ONE*, **2018**, 13, e0198038	3.7	21
89	Genetic Basis, Expression Patterns and Clinical Significance of PD-L1 in Peripheral T-Cell Lymphomas (PTCL). *Blood*, **2018**, 132, 2868-2868	2.2	1
88	Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. *PLoS ONE*, **2018**, 13, e0192839	3.7	2

87	The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL). *Blood*, **2018**, 132, 4130-4130	2.2	0
86	Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia. *Blood*, **2018**, 132, 5569-5569	2.2	
85	Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study. *British Journal of Haematology*, **2018**, 182, 590-594	4.5	2
84	Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013. *Leukemia and Lymphoma*, **2017**, 58, 1219-1223	1.9	4
83	T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. *Haematologica*, **2017**, 102, 562-572	6.6	89
82	Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia. *Annals of Hematology*, **2017**, 96, 1681-1691	3	10
81	Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. *Cancer Immunology, Immunotherapy*, **2017**, 66, 91-102	7.4	7
80	EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. *Oncotarget*, **2017**, 8, 10213-10224	3.3	37
79	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. *Oncotarget*, **2017**, 8, 103731-103743	3.3	16
78	Ibrutinib-A double-edge sword in cancer and autoimmune disorders. *Journal of Drug Targeting*, **2016**, 24, 373-85	5.4	17
77	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. *Lancet Oncology, The*, **2016**, 17, 1409-1418	21.7	233
76	Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions. *Oncology Letters*, **2016**, 12, 2782-2788	2.6	5
75	Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2016**, 57, 2037-46	1.9	16
74	New perspectives on complement mediated immunotherapy. *Cancer Treatment Reviews*, **2016**, 45, 68-75	14.4	8
73	Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study. *Experimental Hematology*, **2016**, 44, 38-49.e1	3.1	4
72	Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. *Oncotarget*, **2016**, 7, 6809-23	3.3	47
71	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. *Haematologica*, **2016**, 101, 1573-1580	6.6	88
70	Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. *Tumor Biology*, **2016**, 37, 11947-11957	2.9	20

69	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. *Haematologica*, **2015**, 100, e311-4	6.6	12
68	Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. *Molecular Immunology*, **2015**, 66, 164-70	4.3	21
67	Dendritic cell regulation of NK-cell responses involves lymphotoxin-IL-12, and TGF-*European Journal of Immunology*, **2015**, 45, 1783-93	6.1	24
66	Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. *British Journal of Haematology*, **2015**, 170, 40-9	4.5	12
65	Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program. *Blood*, **2015**, 126, 1745-1745	2.2	3
64	Comparison of Phase 3 Ibrutinib Results Versus Standard of Care in Sweden in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). *Blood*, **2015**, 126, 1751-1751	2.2	1
63	First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells. *Blood*, **2015**, 126, 2912-2912	2.2	2
62	In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study. *Blood*, **2015**, 126, 4164-4164	2.2	3
61	Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. *Blood*, **2015**, 126, 833-833	2.2	4
60	A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL.. *Journal of Clinical Oncology*, **2015**, 33, 8556-8556	2.2	1
59	Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia. *PLoS ONE*, **2015**, 10, e0142310	3.7	7
58	A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update. *Blood*, **2015**, 126, 1734-1734	2.2	
57	The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy. *Seminars in Cancer Biology*, **2014**, 29, 21-31	12.7	68
56	Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review. *Critical Reviews in Oncology/Hematology*, **2014**, 89, 1-15	7	47
55	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE17 Trial. *Blood*, **2014**, 124, 327-327	2.2	29
54	Ofatumumab (OFA) Vs. Physician Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242. *Blood*, **2014**, 124, 4684-4684	2.2	4
53	Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients. *Blood*, **2014**, 124, 4685-4685	2.2	1
52	a Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). *Blood*, **2014**, 124, 4686-4686	2.2	3

51	An Epigenomic Map of Multiple Myeloma Reveals the Importance of Polycomb Gene Silencing for the Malignancy. *Blood*, **2014**, 124, 2192-2192	2.2	
50	Apoptosis induction mediated through PI3-kinase/AKT/mTOR pathway using anti-ROR1 monoclonal antibody in chronic lymphocytic leukemia cells.. *Journal of Clinical Oncology*, **2013**, 31, 7087-7087	2.2	1
49	Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. *Cancer Immunology, Immunotherapy*, **2012**, 61, 865-79	7.4	37
48	Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.. *Journal of Clinical Oncology*, **2012**, 30, 6584-6584	2.2	
47	Phosphorylation of Receptor Tyrosine Kinase ROR1 At Tyrosine 641, 646 and Serine 652 residues Might Be of Importance for the Survival of CLL Leukemic Cells. *Blood*, **2012**, 120, 3885-3885	2.2	
46	ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells. *Blood*, **2011**, 118, 1778-1778	2.2	2
45	Patients with Chronic Lymphocyte Leukemia (CLL) Have Naturally Occurring Antibodies Against the Receptor Tyrosine Kinase (ROR1). *Blood*, **2011**, 118, 1771-1771	2.2	
44	Ofatumumab, a human anti-CD20 monoclonal antibody. *Expert Opinion on Biological Therapy*, **2010**, 10, 439-49	5.4	15
43	Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (. *Blood*, **2010**, 116, 111-111	2.2	1
42	Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL). *Blood*, **2010**, 116, 2413-2413	2.2	
41	T Cells From CLL Patients Recognize Spontaneously Peptides Derived of the Receptor Tyrosine Kinase Ror1. *Blood*, **2010**, 116, 3603-3603	2.2	
40	Advances in LLM. Ofatumumab: a new agent for chronic lymphocytic leukemia. *Clinical Advances in Hematology and Oncology*, **2010**, 8, 28-30	0.6	
39	Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. *Current Hematologic Malignancy Reports*, **2009**, 4, 47-53	4.4	18
38	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International	2.2	21
37	The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study. *Blood*, **2008**, 112, 839-839	2.2	2
36	T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.. *Blood*, **2008**, 112, 2071-2071	2.2	1
35	Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. *British Journal of Haematology*, **2007**, 136, 736-44	4.5	14
34	Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. *European Journal of Cancer*, **2007**, 43, 510-9	7.5	66

33	Zanolimumab (HuMax-CD4): a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.. *Blood*, **2007**, 110, 3409-3409	2.2	10
32	Comparison of Gene Expression between T Cells from CLL Patients, Myeloma Patients and Healthy Individuals.. *Blood*, **2007**, 110, 4674-4674	2.2	
31	Selective Inhibition of Glycogen Synthase Kinase-3 by Facilitators of Insulin Response Promotes Proliferation and Survival in Multiple Myeloma Cells.. *Blood*, **2007**, 110, 4789-4789	2.2	
30	Immunological Responses in CLL Patients Vaccinated with Autologous Dendritic Cells Loaded with Apoptotic Bodies (Apo-DC).. *Blood*, **2007**, 110, 2061-2061	2.2	
29	Strategies in the management of alemtuzumab-related side effects. *Seminars in Oncology*, **2006**, 33, S29-35	3.5	39
28	Functional Iron Deficiency Effectively Overcome by Adjuvant IV Iron during Epoetin Treatment.. *Blood*, **2006**, 108, 3725-3725	2.2	
27	Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. *British Journal of Haematology*, **2005**, 129, 206-9	4.5	52
26	New erythropoietic proteins: rationale and clinical data. *Seminars in Oncology*, **2004**, 31, 12-8	5.5	6
25	First Analysis of the Completed Mabthera International (Mint) Trial in Young Patients with Low-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Addition of Rituximab to a CHOP-Like Regimen Significantly Improves Outcome of All Patients with the Identification of a Very Favorable Subgroup with IPI=0 and No Bulky Disease.. *Blood*, **2004**, 104, 157-157	2.2	28
24	CERA (Continuous Erythropoietin Receptor Activator): Dose-Response Trial of Subcutaneous (SC) Administration Once Every 3 Weeks (Q3W) to Patients with Aggressive Non-Hodgkin Lymphoma and Anemia Receiving Chemotherapy.. *Blood*, **2004**, 104, 4225-4225	2.2	3
23	Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in Multiple Myeloma Cells Using Selective IGF-IR Tyrosine Kinase Inhibitors.. *Blood*, **2004**, 104, 639-639	2.2	1
22	T-Cell Function in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Following Alemtuzumab (Campath) or Fludarabine Treatment.. *Blood*, **2004**, 104, 2513-2513	2.2	
21	Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. *Medical Oncology*, **2002**, 19 Suppl, S21-6	3.7	21
20	Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. *Journal of Clinical Oncology*, **2002**, 20, 2486-94	2.2	269
19	Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern. *British Journal of Haematology*, **2001**, 115, 263-71	4.5	25
18	Interleukin-10 gene promoter polymorphisms in multiple myeloma. *International Journal of Cancer*, **2001**, 95, 184-8	7.5	42
17	Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. *British Journal of Haematology*, **2000**, 111, 230-238	4.5	
16	Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, **2000**, 111, 608-617	4.5	

15	Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma. *Acta Oncologica*, **2000**, 39, 797-800	3.2	17
14	Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. *British Journal of Haematology*, **2000**, 111, 230-8	4.5	25
13	The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. *European Journal of Haematology*, **1999**, 63, 163-70	3.8	19
12	T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. *International Journal of Cancer*, **1999**, 80, 671-80	7.5	38
11	T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden. *European Journal of Immunology*, **1997**, 27, 2245-52	6.1	55
10	Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. *British Journal of Haematology*, **1996**, 92, 71-6	4.5	22
9	Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?. *Medical Oncology*, **1996**, 13, 1-7	3.7	25
8	Cytokine therapy in multiple myeloma. *British Journal of Haematology*, **1996**, 94, 425-32	4.5	15
7	Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. *British Journal of Haematology*, **1996**, 93, 151-3	4.5	197
6	Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. *British Journal of Haematology*, **1995**, 89, 110-6	4.5	56
5	Chemotherapy and immunotherapy of colorectal cancer. *Medical Oncology and Tumor Pharmacotherapy*, **1991**, 8, 207-20		10
4	Oral melphalan pharmacokinetics: influence of interferon-induced fever. *Clinical Pharmacology and Therapeutics*, **1990**, 47, 86-90	6.1	14
3	Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma. *Medical Oncology and Tumor Pharmacotherapy*, **1989**, 6, 151-4		20
2	Human monoclonal immunoglobulins that bind the human acetylcholine receptor. *European Journal of Immunology*, **1987**, 17, 1867-9	6.1	19
1	Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron. *Nature Medicine*,	50.5	0